Systematic review: hydroxyurea for the treatment of adults with sickle cell disease. (apre una nuova finestra)

Lanzkron S, Strouse JJ, Wilson R, Beach MC, Haywood C, Park H, Witkop C, Bass EB, Segal JB.

Fonte‎: Ann Intern Med 2008;148(12):939-55.

Indicizzato‎: PubMed 18458272

https://www.ncbi.nlm.nih.gov/pubmed/18458272 (apre una nuova finestra)

Cost-effectiveness of hydroxyurea in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. (apre una nuova finestra)

Moore RD, Charache S, Terrin ML, Barton FB, Ballas SK.

Fonte‎: Am J Hematol 2000;64(1):26-31.

Indicizzato‎: PubMed 10815784

https://www.ncbi.nlm.nih.gov/pubmed/10815784 (apre una nuova finestra)

Hydroxyurea for the treatment of sickle cell anemia. (apre una nuova finestra)

Platt OS.

Fonte‎: N Engl J Med 2008;358(13):1362-9.

Indicizzato‎: PubMed 18367739

DOI‎: 10.1056/NEJMct0708272

https://www.ncbi.nlm.nih.gov/pubmed/18367739 (apre una nuova finestra)

Clinical effectiveness of decitabine in severe sickle cell disease. (apre una nuova finestra)

Saunthararajah Y, Molokie R, Saraf S, Sidhwani S, Gowhari M, Vara S, Lavelle D, DeSimone J.

Fonte‎: Br J Haematol 2008;141(1):126-9.

Indicizzato‎: PubMed 18324975

DOI‎: 10.1111/j.1365-2141.2008.07027.x

https://www.ncbi.nlm.nih.gov/pubmed/18324975 (apre una nuova finestra)

The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS). (apre una nuova finestra)

Voskaridou E, Christoulas D, Bilalis A, Plata E, Varvagiannis K, Stamatopoulos G, Sinopoulou K, Balassopoulou A, Loukopoulos D, Terpos E.

Fonte‎: Blood 2010;115(12):2354-63.

Indicizzato‎: PubMed 19903897

DOI‎: 10.1182/blood-2009-05-221333

https://www.ncbi.nlm.nih.gov/pubmed/19903897 (apre una nuova finestra)

Prophylactic antibiotics for preventing pneumococcal infection in children with sickle cell disease. (apre una nuova finestra)

Hirst C, Owusu-Ofori S.

Fonte‎: Cochrane Database Syst Rev 2012;(9):CD003427.

Indicizzato‎: PubMed 22972063

DOI‎: 10.1002/14651858.CD003427.pub2

https://www.ncbi.nlm.nih.gov/pubmed/22972063 (apre una nuova finestra)

Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial. (apre una nuova finestra)

Howard J, Ataga KI, Brown RC, Achebe M, Nduba V, El-Beshlawy A, Hassab H, Agodoa I, Tonda M, Gray S, Lehrer-Graiwer J, Vichinsky E

Fonte‎: Lancet Haematol 2021;8(5):e323-33.

Indicizzato‎: PubMed 33838113

DOI‎: 10.1016/S2352-3026(21)00059-4

https://www.ncbi.nlm.nih.gov/pubmed/33838113 (apre una nuova finestra)

Sickle cell disease. (apre una nuova finestra)

Meremikwu MM, Okomo U.

Fonte‎: BMJ Clin Evid 2011;02:2402.

Indicizzato‎: PubMed 21718552

https://www.ncbi.nlm.nih.gov/pubmed/21718552 (apre una nuova finestra)

A phase 3 trial of l-glutamine in sickle cell disease. (apre una nuova finestra)

Niihara Y, Miller ST, Kanter J, Lanzkron S, Smith WR, Hsu LL, Gordeuk VR, Viswanathan K, Sarnaik S, Osunkwo I, Guillaume E, Sadanandan S, Sieger L, Lasky JL, Panosyan EH, Blake OA, New TN, Bellevue R, Tran LT, Razon RL, Stark CW, Neumayr LD, Vichinsky EP

Fonte‎: N Engl J Med 2018;379(3):226-35.

Indicizzato‎: PubMed 30021096

DOI‎: 10.1056/NEJMoa1715971

https://www.ncbi.nlm.nih.gov/pubmed/30021096 (apre una nuova finestra)

Malaria chemoprophylaxis in sickle cell disease. (apre una nuova finestra)

Oniyangi O, Omari AA.

Fonte‎: Cochrane Database Syst Rev 2006;(4):CD003489.

Indicizzato‎: PubMed 17054173

DOI‎: 10.1002/14651858.CD003489.pub2

https://www.ncbi.nlm.nih.gov/pubmed/17054173 (apre una nuova finestra)